Navigation Links
1,200th Worldwide Implant of the SynCardia Total Artificial Heart Occurs in Indiana
Date:11/12/2013

TUCSON, Ariz., Nov. 12, 2013 /PRNewswire/ -- An Indiana man has become the 1,200th person in the world to be implanted with the SynCardia temporary Total Artificial Heart. Patrick O'Hara is the first person in Indiana to receive the life-saving device and the first Hoosier to be discharged from the hospital with the Freedom® portable driver.

(Photo: http://photos.prnewswire.com/prnh/20131112/LA14803)

On June 26, 2013, O'Hara, 59, received the SynCardia Total Artificial Heart at Indiana University Health Methodist Hospital as a bridge to transplant. It's the only device that eliminates the source and symptoms of biventricular (both sides) heart failure. Dr. I-wen Wang, M.D., Ph.D., an IU Health cardiothoracic surgeon who specializes in heart and lung transplantation and ventricular-assist devices, implanted the SynCardia Heart when O'Hara's own organ, weakened by 30 years of heart disease, began to fail.

"Mr. O'Hara went from having blue fingertips from lack of sufficient blood flow to walking out of the hospital on his own power," says Dr. Wang. "The SynCardia Total Artificial Heart has given him a chance to get stronger in preparation for his heart transplant."

O'Hara left IU Health Methodist Hospital on October 10 carrying the 13.5-pound wearable Freedom driver in the backpack. Powered by two lithium batteries, the driver provides precisely calibrated pulses of air to operate the SynCardia Heart.

The Freedom portable driver allows patients to be discharged to their home and community to wait for a donor heart. Almost all of what would have been O'Hara's in-hospital costs have been eliminated for this portion of his care. O'Hara is undergoing outpatient cardiac rehabilitation to regain his strength. He's also looking forward to fishing and eating out at restaurants.

"It's mind-blowing how technology has advanced to create new possibilities for patients with end-stage heart disease," says Dr. Wang. "Heart devices have evolved for the benefit of all patients."

SynCardia Systems Inc. manufactures the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. Like a donor heart, the SynCardia Heart replaces both failing heart ventricles and the four heart valves.

Originally used as a permanent replacement heart, the SynCardia Heart currently is approved as a bridge to transplant. A 10-year pivotal clinical study showed that the SynCardia Total Artificial Heart had a 79% bridge to transplant rate, which is the highest transplant rate for any approved heart device in the world.

O'Hara's June 26 surgery marked the 1,200th time the SynCardia Total Artificial Heart has been implanted. Since then the number of implants have reached nearly 1,250, accounting for more than 335 patient years of life on the device. So far this year more than 135 SynCardia Hearts have been implanted, more than in all of 2012.

IU Health Methodist Hospital is among 93 SynCardia Certified Centers worldwide. Another 35 medical centers are in the process of certification.

"Surgeons around the world are finding more reasons to implant the SynCardia Total Artificial Heart to help end-stage biventricular heart failure patients," says Michael P. Garippa, CEO and president of SynCardia Systems.

The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

CAUTION - The Freedom portable driver is an investigational device, limited by United States law to investigational use.

Read IU Health's press release and watch video about Patrick O'Hara.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Worldwide Vital Signs Monitoring Market Report 2013-2018: Blood Pressure Monitoring Devices, Pulse Oximeters and Temperature Monitoring Devices
2. CPhI Annual Expert Industry Report (Part II): Live from CPhI Worldwide
3. Capsugel Previews New Generation, Easy-to-Open Sprinkle Capsule at CPhI Worldwide and AAPS Annual Meeting and Exposition
4. Surgeons Worldwide Implanted a Record 125 SynCardia Total Artificial Hearts So Far in 2013
5. 15 October 2013 Breast Health Day: From Spain to Tajikistan, from Israel to Sweden, a Day Dedicated to the Breast Health of Women Worldwide
6. Tele-Health Carts, Servers, and Monitoring Worldwide, 2012 to 2018
7. Portable Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2018
8. Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2018
9. Femtosecond Lasers for Cataract Surgery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018
10. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
11. Over 55 Industry Experts Expected to Attend CPhI Worldwides Pre-Connect Conference - the Pharma Industrys Leading Global Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):